In preclinical models, a chemically defined synthetic MUC1 glycopeptide vaccine directed at tumor-associated epitopes such as sTn elicited strong Th1-biased responses and activated cytotoxic T cells in murine PDAC [50]. This evidence concerns the gene MUC1 and neoplasm.